GSK

GSK (formerly GlaxoSmithKline) is one of the world's largest research-based pharmaceutical and vaccine companies, with a history stretching back more than 300 years through its predecessor organisations. Headquartered in London, GSK employs tens of thousands of people across more than 75 countries and serves patients in over 150 markets worldwide. The company completed a major strategic transformation in 2022, separating its consumer healthcare division into a standalone business (Haleon), allowing GSK to focus exclusively on biopharma innovation.

Vaccines & Infectious Disease Leadership

GSK is one of the world's leading vaccine manufacturers, with an extensive portfolio covering infectious diseases including influenza, shingles, meningitis, hepatitis, and respiratory syncytial virus (RSV). Its Shingrix vaccine for shingles became one of the most commercially significant vaccine launches in the company's history. GSK's vaccine research and manufacturing infrastructure spans multiple continents, supporting both commercial markets and global health programmes in lower-income countries.

Oncology & Specialty Medicines Pipeline

Beyond vaccines, GSK has built a growing presence in oncology, HIV, respiratory disease, and immunology. Through its long-standing collaboration and partial ownership of ViiV Healthcare, GSK holds a leading position in HIV treatment and prevention, including long-acting injectable regimens that have reshaped clinical standards of care. The company's oncology pipeline targets areas including gynaecological cancers and haematological malignancies. In respiratory medicine, GSK has decades of heritage in treatments for asthma and chronic obstructive pulmonary disease.

GSK is listed on the London Stock Exchange (LSE: GSK) and on the New York Stock Exchange as an American depositary receipt (NYSE: GSK). The company invests heavily in research and development, with a stated commitment to using genetics and advanced science to identify and validate new targets across its core therapy areas. Its R&D operations are spread across major hubs in the United Kingdom, the United States, and Belgium.

Further information is available at gsk.com.